Best CAR T Cell Therapy in India
At BMT Next, we offer the best CAR T Cell Therapy in India, combining advanced cellular immunotherapy with expert hematology care. This revolutionary treatment—Chimeric Antigen Receptor T-Cell Therapy—is changing the way we treat blood cancers like leukemia, lymphoma, and multiple myeloma, especially in relapsed or refractory patients. Our state-of-the-art CAR T facilities, available in Gurgaon, Faridabad, Hisar, and for international patients in Mauritius, ensures every patient receives personalized, precision-targeted therapy designed to save lives when traditional options have failed.
BMT Next is leading India’s CAR TTherapy revolution, making this once-inaccessible therapy affordable, accessible, and effective for patients across the globe.
who neet car t cell therapy
CAR T Cell Therapy in India is a transformative treatment designed for patients with relapsed or refractory blood cancers who have failed to respond to conventional therapies like chemotherapy, radiation, or bone marrow transplant. At BMT Next, we offer the best CAR T Cell Therapy tailored to patients who require next-generation care when all other options have been exhausted.
This personalized immunotherapy works by genetically reprogramming the patient’s own T-cells to recognize and destroy cancer cells with high precision. It is particularly effective for patients who experience disease progression despite undergoing multiple lines of treatment.
when is car t cell therapy recommended
CAR T Cell Therapy is recommended in the below situations:
- Failure of two or more lines of chemotherapy
- Relapse after bone marrow or stem cell transplant
- Positive minimal residual disease (MRD) after getting initial remission
- Ineligibility for transplant due to age, comorbidities, or poor organ function
- Rapidly progressing blood cancer despite aggressive treatment
- Pediatric patients with high-risk, relapsed acute lymphoblastic leukemia
BMT Next follows internationally accepted clinical criteria to identify candidates for Best CAR T Cell Therapy in Gurgaon, Faridabad, Hisar, and Mauritius.
who may not be eligible for car t therapy in india
- All steps from leukapheresis to infusion are done under one umbrella
- Use of both India-developed and international CAR constructs
- Lowest contamination risk is there due to closed-system CAR T processing
- Integrated transplant and ICU team ensures 24×7 response readiness
- Strict adherence to ICMR, DCGI, and international CAR T protocols
However, BMT Next employs multidisciplinary strategies such as bridging therapy, infection control, and optimization of organ function to make high-risk patients eligible whenever possible.
Global and National Access to CAR T Cell Therapy
BMT Next delivers Best CAR T Cell Therapy in multiple locations including Gurgaon, Faridabad, Hisar, and internationally in Mauritius. Patients from across India and abroad seek our expert-led, protocol-driven CAR T programs. We offer the best Cart T Cell treatment in Gurgaon, Hisar, Faridabad, and Mauritius. We offer language support, international patient coordination, and pre-arrival evaluations for seamless integration into our care pathways.
Why Choose BMT Next for Best CAR T Cell Therapy in India
BMT Next is India’s leading destination for patients seeking reliable, cutting-edge, and affordable CAR T Cell Therapy. With a proven record in hematology, immunotherapy, and transplant science, BMT Next has positioned itself as a the best CAR T Cell Therapy center in India, offering holistic and result-oriented treatment for relapsed and refractory blood cancers.
We are among the few centers in India to offer comprehensive CAR T programs that span from T-cell collection and genetic modification to infusion and post-treatment monitoring, all under one coordinated clinical team. Patients from across India—Gurgaon, Faridabad, Hisar—and from overseas locations such as Mauritius trust BMT Next for its unmatched combination of clinical excellence, innovation, and compassionate care.
A Dedicated Team of India’s Best CAR T Cell Therapy Experts
The success of CAR T Cell Therapy heavily depends on clinical experience, multidisciplinary planning, and rapid decision-making. At BMT Next, the therapy is delivered by a high-caliber team of board-certified specialists:
- Meet Kumar, Director & HOD – DM Clinical Hematology; over 2000 successful BMTs; trained in CAR T therapy at King’s College London; awarded ‘Hisar Gaurav’
- Neeraj Teotia, Pediatric Consultant – 1000+ pediatric BMTs; international training in pediatric immunotherapy and leukapheresis
- Umesh Kumar, Consultant – 800+ successful bone marrow and cell therapy cases; expert in CAR T for refractory leukemia and lymphoma; trained in Israel
- Sumit Joshi, Senior Transplant Supervisor – oversees ICU safety, toxicity response, and 24×7 post-infusion care
This collective expertise ensures personalized and Best CAR T Cell Therapy in India, tailored to individual genetic and disease profiles.
In-House GMP CAR T Lab and Advanced Cellular Engineering
BMT Next is one of the few Indian centers with access to a GMP-certified, closed-loop T-cell engineering facility, ensuring safety, sterility, and compliance with international regulatory standards. We use:
- Leukapheresis systems for efficient T-cell collection
- Next-generation gene modification platforms
- Controlled CAR transduction with CD19 and BCMA targets
- Rapid turnaround in cell expansion and cryopreservation
- DCGI and ICMR-approved CAR constructs for Indian patients
This infrastructure allows us to maintain cell viability, reduce treatment delays, and guarantee protocol fidelity across all sites—making it a top CAR T Cell hospital in India.
ICU-Integrated, HEPA-Protected Infusion Wards
Safety during CAR T infusion and post-infusion monitoring is highly important. Our centers in Gurgaon, Faridabad, Hisar, and Mauritius offer:
- Positive pressure rooms with HEPA filtration
- High-dependency units for immediate ICU escalation
- Round-the-clock hematology-trained critical care staff
- Emergency management of Cytokine Release Syndrome (CRS) and ICANS
- Access to tocilizumab, steroids, and neuroprotection protocols
This allows us to deliver Best CAR T Cell Therapy in India with international-level safety standards, ensuring patients and families feel secure throughout the treatment journey.
High Response Rates, Durable Remissions, and Transparent Outcomes
BMT Next has achieved excellent remission rates in patients with relapsed DLBCL, refractory ALL, and multiple myeloma. We monitor patients with advanced MRD (Minimal Residual Disease) assays, imaging, and molecular response tracking. Our published outcomes show:
- 75% remission in pediatric ALL post-CAR T
- ~60% durable responses in DLBCL with bridging therapy
- Increasing adoption of BCMA-targeted CAR T for relapsed myeloma in adults
We provide detailed treatment plans, success metrics, and independent data audits to maintain transparency and trust.
Patient-Centric Support for Every Stage of the CAR T Journey
From diagnosis to remission, BMT Next delivers:
- Pre-evaluation, second opinions, and cost counseling
- Coordination for insurance, PMJAY, or CSR funding where applicable
- Dedicated international desk for visa support, travel, and follow-up
- Long-term survivorship, mental health support, and reintegration programs
Whether you’re looking for affordable CAR T Cell Therapy in India or premium support as an international patient, BMT Next ensures continuity, compassion, and clarity.
CAR T Cell Therapy Process at BMT Next
At BMT Next, we follow a well-structured, internationally standardized protocol for delivering Best CAR T Cell Therapy in India, designed to ensure patient safety, treatment efficacy, and long-term remission. Each step is managed by our specialized hemato-oncology and transplant team, with seamless coordination across diagnostics, cell processing, and supportive care.
Our CAR T program combines advanced clinical technology with personalized treatment planning to offer precision immunotherapy for blood cancer patients in Gurgaon, Faridabad, Hisar, and Mauritius.
Step-by-Step CAR T Cell Therapy Workflow
1. Patient Evaluation & Eligibility Assessment
Patients are first assessed based on:
- Diagnosis of relapsed/refractory leukemia, lymphoma, or myeloma
- Tumor marker expression (e.g., CD19+, BCMA+)
- Performance status, organ function, infection profile
- Prior treatment history and disease response
BMT Next uses comprehensive blood tests, flow cytometry, PET-CT, and genetic profiling to determine suitability for CAR T.
2. Leukapheresis – T Cell Collection
Eligible patients undergo leukapheresis, a procedure to extract T-cells from the bloodstream using a specialized apheresis machine. This is done in our in-house, cleanroom-equipped cellular therapy unit.
3. T Cell Engineering in GMP-Compliant Lab
The collected T-cells are transported to our GMP-certified CAR T lab, where they are genetically modified using viral vectors to express Chimeric Antigen Receptors (CARs) that can target specific cancer cells.
BMT Next currently uses:
- CD19 CAR constructs for B-cell leukemias and lymphomas
- BCMA CAR constructs for relapsed multiple myeloma
The modified cells are then expanded, quality-checked, and cryopreserved for infusion.
4. Conditioning Chemotherapy
Before infusion, patients receive a short course of lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) to suppress the immune system and prepare the body for the CAR T cells to function optimally.
5. CAR T Cell Infusion
The modified T-cells are thawed and infused intravenously under strict ICU surveillance. The process is similar to a blood transfusion and usually takes 30–60 minutes.
Infusion is done in:
- HEPA-filtered isolation rooms
- ICU-monitored wards with transplant-trained nursing
Real-time monitoring of vital signs and inflammatory markers
6. Monitoring for Toxicities
Post-infusion, patients are monitored for:
- Cytokine Release Syndrome (CRS) – Managed with tocilizumab and corticosteroids
- Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) – It’s managed with neurological observation protocols
- Tumor Lysis Syndrome, cytopenias, and sepsis risk
BMT Next maintains ICU-level readiness during the first 14–21 days of post-infusion care.
7. Response Evaluation and Follow-Up
- MRD testing, bone marrow biopsies, and imaging are used to check treatment response
- Long-term follow-up at Day +30, +100, +180, and annually
Survivorship programs and late-effect monitoring for pediatric and adult patients
Why Our Process Is Unique for Car T Cell Treatment?
- All steps from leukapheresis to infusion are done under one umbrella
- Use of both India-developed and international CAR constructs
- Lowest contamination risk is there due to closed-system CAR T processing
- Integrated transplant and ICU team ensures 24×7 response readiness
- Strict adherence to ICMR, DCGI, and international CAR T protocols
Cost of CAR T Cell Therapy in India
Understanding the cost of CAR T Cell Therapy in India is crucial for patients and families exploring this advanced treatment. While this therapy is one of the most cutting-edge cancer treatments available globally, BMT Next is committed to making it accessible and affordable, especially for Indian patients and those coming from low- and middle-income countries.
Our pricing is transparent, inclusive of all major steps—from evaluation to post-infusion care—and we provide customized financial guidance based on cancer type, patient condition, and response requirements.
Average Cost of CAR T Cell Therapy at BMT Next
The typical cost range for CAR T Cell Therapy in India at BMT Next is:
₹35,00,000 to ₹55,00,000 INR
(Approximately $42,000 to $66,000 USD)
This cost includes:
- Initial consultation and diagnostic profiling
- Leukapheresis (T-cell collection)
- CAR T cell manufacturing (in-house or partner labs)
- Lymphodepleting chemotherapy
- CAR T infusion
- 14–21 days of post-infusion ICU/ward care
- CRS/ICANS management
- Response monitoring (MRD, PET-CT, marrow testing)
- Nutritional, psychological, and survivorship support
We ensure no hidden charges, and every patient receives a detailed estimate before starting therapy. We are considered the best bone marrow bone marrow transplant center in gurgaon!
Factors That Influence CAR Therapy Cost
The final cost may vary depending on:
- Type of CAR construct used (CD19, BCMA, or other)
- Whether autologous (patient’s own) or allogeneic CAR T is used
- Site of treatment (Gurgaon, Faridabad, Hisar, Mauritius)
- ICU admission and post-treatment complication management
- Type of blood cancer and treatment duration
- Choice of India-developed vs imported CAR constructs
BMT Next offers both indigenous (Made in India) CAR T therapies and access to internationally validated constructs, depending on clinical need and financial feasibility.
Insurance, CSR Support, and Financial Counseling
BMT Next’s finance and insurance desk supports patients through:
- Government schemes like PMJAY and CGHS (where eligible)
- Corporate CSR programs for underprivileged families
- Tie-ups with international patient funds and global NGOs
- EMI-based financing options in collaboration with healthcare lenders
- Pre-approval documentation for private health insurance policies
We assist both Indian and international patients in accessing the best possible financial route to begin treatment without delay.
Why BMT Next Offers Superior Value
While the cost of CAR T Cell Therapy in India is significantly lower than in the US or Europe (where it ranges from ₹3–5 Cr or $400,000–700,000), BMT Next delivers:
- Comparable efficacy using DCGI/FDA-compliant CAR constructs
- In-house CAR T processing for faster turnaround and cost benifits
- ICU-integrated units at no additional escalation cost
- Personalized monitoring and long-term follow-up
- Dedicated support for pediatric and international patients
This makes BMT Next a top choice for patients seeking high-quality yet affordable CAR T treatment across India.
Patient Success Stories & Testimonials
CAR T Cell Therapy Outcomes at BMT Next
CAR T Cell Therapy is more than a scientific innovation—it’s a lifeline for patients facing aggressive, relapsed, or treatment-resistant blood cancers. At BMT Next, we have helped transform outcomes for children, young adults, and seniors who were previously left with no viable options.
These case studies highlight the real impact of CAR T Cell Therapy in India—delivered with precision, compassion, and expertise by the team at BMT Next.
Aarav M. – Pediatric Relapsed B-Cell Acute Lymphoblastic Leukemia (ALL)
Age: 11 years | Location: Hisar, Haryana
Diagnosis: B-ALL, MRD-positive relapse post two failed chemo protocols
Severity: High-risk cytogenetics, 70% blast load at relapse, no transplant donor match
Treatment at BMT Next:
- CD19-targeted CAR T Cell Therapy initiated within 3 weeks of referral
- Received fludarabine + cyclophosphamide lymphodepletion followed by CAR T infusion
- Developed Grade 1 Cytokine Release Syndrome, managed without ICU support
- Day +30: MRD-negative status confirmed via flow cytometry
- Returned to full activity in 2 months
- Maintains remission at 14 months of follow-up
Outcome: Durable remission with excellent post-treatment quality of life
Mr. Ramesh T. – Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Age: 52 years | Location: Mauritius
Diagnosis: Stage IV DLBCL, failed R-CHOP and ICE chemotherapy
Severity: Chemoresistant disease with mediastinal mass and bone marrow infiltration; transplant ineligible due to EF <40% (cardiac dysfunction)
Treatment at BMT Next, Gurgaon:
- Pre-treated with bridging therapy to reduce tumor burden
- CD19-specific CAR T infusion under ICU monitoring
- Developed Grade 2 CRS managed with Tocilizumab
- Day +30: 60% tumor reduction on PET
- Day +90: Complete Metabolic Response
- Continues maintenance follow-up via our Mauritius satellite team
Outcome: Transplant-free remission with restored organ work and full return to work
Mrs. Nidhi V. – Triple Refractory Multiple Myeloma
Age: 45 years | Location: Faridabad, India
Diagnosis: Relapsed IgG kappa multiple myeloma, refractory to bortezomib, lenalidomide, and daratumumab
Severity: Extensive lytic bone lesions, anemia, creatinine 2.1 mg/dL, ECOG 2
Treatment at BMT Next:
- Treated with BCMA-targeted CAR T Cell Therapy under early-access protocol
- Post-infusion developed transient cytopenias, no neurotoxicity
- Day +100 marrow showed no clonal plasma cells
- Free light chain ratio normalized
- Patient resumed daily function, physiotherapy ongoing for skeletal recovery
Outcome: Clinical and biochemical remission sustained at 9 months
What Our Patients Say
“We were told to prepare for palliative care. Then we found BMT Next and heard about CAR T therapy. It saved Aarav’s life.” – Aarav’s mother
“I was denied transplant in three countries due to my heart condition. BMT Next gave me hope—and I’m alive to tell the story.” – Ramesh T.
“For years, I lived with bone pain and fear. After CAR T, my myeloma markers are undetectable. BMT Next gave me a new life.” – Nidhi V.
What Sets Our Outcomes Apart
- MRD-negative remission in >75% of pediatric B-ALL cases
- Sustained complete metabolic response in high-risk lymphoma
- Use of bridging chemotherapy to reduce tumor burden pre-infusion
- Controlled toxicities through predictive protocols and ICU-based readiness
- Long-term survivorship tracking with hematology and rehab integration
BMT Next doesn’t just treat disease—we restore futures. Every patient outcome we share is independently verified and documented as part of our commitment to clinical transparency and excellence in Best CAR T Cell Therapy in India.
FAQs
Choose the Best Car-T Treatment Center in India